1
|
Guillo L, Flachaire B, Avouac J, Dong C, Nachury M, Bouguen G, Buisson A, Caillo L, Fumery M, Gilletta C, Hébuterne X, Lafforgue P, Laharie D, Mahé E, Marotte H, Nancey S, Ottaviani S, Salmon JH, Savoye G, Serrero M, Uzzan M, Viguier M, Richez C, Peyrin-Biroulet L, Seksik P, Pham T. Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study. Dig Liver Dis 2023; 55:61-68. [PMID: 35985961 DOI: 10.1016/j.dld.2022.07.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/13/2022] [Revised: 07/19/2022] [Accepted: 07/20/2022] [Indexed: 12/31/2022]
Abstract
BACKGROUND Use of a combination of targeted therapies (COMBIO) in patients with refractory/overlapping immune-mediated inflammatory diseases (IMIDs) has increased, but reported data remain scarce. We aimed to assess effectiveness and safety of COMBIO in patients with IMIDs. METHODS We conducted a French ambispective multicenter cohort study from September 2020 to May 2021, including adults' patients with 1 or 2 IMIDs and treated at least 3-month with COMBIO. RESULTS Overall, 143 patients were included. The most common IMIDs were Crohn's disease (63.6%), axial spondyloarthritis (37.7%), and ulcerative colitis (14%). Half of patients had only one IMID, of which 60% were Crohn's disease. Mean duration of COMBIO was 274.5±59.3 weeks, and COMBIO persistence at 104 weeks was estimated at 64.1%. The most frequent COMBIOs combined anti-TNF agents with vedolizumab (30%) or ustekinumab (28.7%). Overall, 50% of patients achieved significant and 27% mild-to-moderate improvement in patient-reported outcomes. Extended duration of COMBIO (aOR=1.09; 95% CI: 1.03-1.14; p=0.002) and diagnoses of two IMIDs (aOR=3.46; 95%CI: 1.29-9.26; p=0.013) were associated with significant improvement in patient-reported outcomes. Incidence of serious infection during COMBIO was 4.51 per 100 person-years (95% CI 2.20-8.27) and 5 COMBIOs were discontinued due to adverse events. CONCLUSIONS COMBIO can be effective and safe in patients with refractory/overlapping IMIDs.
Collapse
Affiliation(s)
- Lucas Guillo
- Aix Marseille Univ, APHM, University Hospital of Marseille Nord, Department of Gastroenterology, Marseille, France.
| | - Benoit Flachaire
- Aix Marseille Univ, APHM, University Hospital of Marseille Sainte-Marguerite, Department of Rheumatology, Marseille, France
| | - Jérôme Avouac
- Université de Paris, service de rhumatologie, hôpital Cochin, AP-HP.CUP, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France
| | - Catherine Dong
- Service de Gastro-Entérologie, Assistance publique-Hôpitaux de Paris (AP-HP), hôpital Bicêtre, 94270 Le Kremlin-Bicêtre, France
| | - Maria Nachury
- Université de Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France
| | - Guillaume Bouguen
- CHU Rennes, Univ Rennes, INSERM, CIC1414, Institut NUMECAN (Nutrition Metabolisms and Cancer), 35000 Rennes, France
| | - Anthony Buisson
- Université Clermont Auvergne, 3iHP, CHU Clermont-Ferrand, Service d'Hépato-Gastroentérologie, Inserm U1071, M2iSH, USC-INRA 2018, Clermont-Ferrand, France
| | - Ludovic Caillo
- Department of Gastroenterology, University Hospital of Nimes, Nimes, France
| | - Mathurin Fumery
- Department of Gastroenterology, Amiens University Medical Center and PeriTox UMR I-O1, Jules Verne University of Picardie, Amiens, France
| | - Cyrielle Gilletta
- Department of Gastroenterology, Toulouse University Hospital, Toulouse, France
| | - Xavier Hébuterne
- Gastroenterology and Clinical Nutrition, CHU of Nice, University Côte d'Azur, Nice, France
| | - Pierre Lafforgue
- Aix Marseille Univ, APHM, University Hospital of Marseille Sainte-Marguerite, Department of Rheumatology, Marseille, France
| | - David Laharie
- CHU de Bordeaux, Hôpital Haut-Lévêque, Service d'Hépato-gastroentérologie et oncologie digestive - Université de Bordeaux, F-33000 Bordeaux, France
| | - Emmanuel Mahé
- Dermatology Department, Hôpital Victor Dupouy, Argenteuil, France. Groupe de recherche sur le Psoriasis (GrPso) de la Société Française de Dermatologie
| | - Hubert Marotte
- Department of Rheumatology, Inserm U1059-LBTO, CHU Saint-Etienne, Saint-Etienne, France
| | - Stéphane Nancey
- Department of Gastroenterology, Inserm U1111-CIRI, Lyon-Sud University Hospital, Hospices Civils de Lyon, Pierre Bénite, France
| | - Sébastien Ottaviani
- Departement of Rheumatology, DMU Locomotion, Hôpital Bichat-Claude Bernard, APHP, Université de Paris, Paris, France
| | - Jean-Hugues Salmon
- Department of Rheumatology and EA 3797, University of Reims Champagne-Ardenne, Reims, France
| | - Guillaume Savoye
- Department of Gastroenterology, Rouen University Hospital, Rouen, France
| | - Mélanie Serrero
- Aix Marseille Univ, APHM, University Hospital of Marseille Nord, Department of Gastroenterology, Marseille, France
| | - Mathieu Uzzan
- Department of Gastroenterology, IBD unit, Beaujon Hospital, APHP, Clichy, France
| | - Manuelle Viguier
- Department of Dermatology-Venereology, Hôpital Robert Debré, Université Reims Champagne-Ardenne, Reims, France
| | - Christophe Richez
- Rheumatology Department, CHU de Bordeaux, and ImmunoConcEpt, CNRS, UMR 5164, University of Bordeaux, Bordeaux, France
| | - Laurent Peyrin-Biroulet
- Department of Gastroenterology and INSERM NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France
| | - Philipe Seksik
- Department of Gastroenterology, Centre de recherche Saint-Antoine, Sorbonne Université, INSERM, APHP, Hôpital Saint-Antoine, Paris, France
| | - Thao Pham
- Aix Marseille Univ, APHM, University Hospital of Marseille Sainte-Marguerite, Department of Rheumatology, Marseille, France
| | | |
Collapse
|
2
|
Turíbio DDCDQ, Oliveira FCS, Barreto SMF, Jabour TBF. Interstitial lung disease due to anti-TNF use in the treatment of psoriasis. An Bras Dermatol 2021; 96:447-450. [PMID: 34001401 PMCID: PMC8245706 DOI: 10.1016/j.abd.2020.08.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2020] [Revised: 08/08/2020] [Accepted: 08/13/2020] [Indexed: 11/01/2022] Open
Abstract
Psoriasis is a chronic inflammatory disease that affects the skin variably, according to genetic and environmental factors. Some patients may benefit from systemic treatment with immunobiological agents, drugs that can be accompanied by several adverse effects. A case of a 58-year-old patient undergoing treatment for psoriasis with adalimumab for five years is reported. Alterations compatible with interstitial pneumonia were detected with important regression after adalimumab discontinuation. This case is relevant due to the scarcity of reports on late pulmonary adverse effect of anti-TNF treatment of psoriasis.
Collapse
|
3
|
Galache Osuna C, Gómez-Vila B, Aubán Pariente J, Vázquez Losada B, Gómez de Castro C, Requena López S, de Dios Velázquez Á, Palacios García L, Ordoñez Fernández L, Gómez Diez S, Vázquez López F, Santos-Juanes J. Ustekinumab Drug Survival in Patients with Psoriasis: A retrospective Study of Real Clinical Practice. Medicina (B Aires) 2020; 56:medicina56110584. [PMID: 33143166 PMCID: PMC7693782 DOI: 10.3390/medicina56110584] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2020] [Revised: 10/27/2020] [Accepted: 10/28/2020] [Indexed: 11/21/2022] Open
Abstract
Background and objectives: The efficacy and safety of ustekinumab have been proved in clinical trials. In daily clinical practice, knowing the factors that determine survival differences of biological drugs allows psoriasis treatment to be optimized as a function of patient characteristics. The main objectives of this work are to understand ustekinumab drug survival in patients diagnosed with plaque psoriasis in the Hospital Universitario Central de Asturias (HUCA Dermatology Department, and to identify the predictors of drug discontinuation. Materials and Methods: A retrospective hospital-based study, including data from 148 patients who were receiving ustekinumab (Stelara®) between 1 February 2009 and 30 November 2019, were collected. Survival curves were approximated through the Kaplan–Meier estimator and compared using the log-rank test. Proportional hazard Cox regression models were used for multivariate analyses while both unadjusted and adjusted hazard ratios (HR) were used for summarizing the studied differences. Results: The average duration of the treatment before discontinuation was 47.57 months (SD 32.63 months; median 41 months). The retention rates were 82% (2 years), 66% (5 years), and 58% (8 years). Median survival was 80 months (95% confidence interval. CI 36.9 to 123.01 months). The survival study revealed statistically significant differences between patients with arthritis (log-rank test, p < 0.001) and those who had previously received biological treatment (log-rank test, p = 0.026). The five-year prevalence in patients still under treatment was 80% (those without arthritis) and 54% (arthritis patients). In the multivariate analysis, only the patients with arthritis had a lower rate of drug survival. No statistically significant differences were observed for any of the other comorbidities studied. The first and second most frequent causes of discontinuation were secondary failure and arthritis inefficacy, respectively. Conclusion: Ustekinumab is a biological drug conferring high survival in plaque psoriasis patients. Ustekinumab survival is lower in patients with arthritis.
Collapse
Affiliation(s)
- Cristina Galache Osuna
- Department of Dermatology, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain; (C.G.O.); (B.G.-V.); (J.A.P.); (B.V.L.); (C.G.d.C.); (S.R.L.); (Á.d.D.V.); (L.P.G.); (S.G.D.); (F.V.L.)
| | - Borja Gómez-Vila
- Department of Dermatology, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain; (C.G.O.); (B.G.-V.); (J.A.P.); (B.V.L.); (C.G.d.C.); (S.R.L.); (Á.d.D.V.); (L.P.G.); (S.G.D.); (F.V.L.)
| | - Javier Aubán Pariente
- Department of Dermatology, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain; (C.G.O.); (B.G.-V.); (J.A.P.); (B.V.L.); (C.G.d.C.); (S.R.L.); (Á.d.D.V.); (L.P.G.); (S.G.D.); (F.V.L.)
| | - Beatriz Vázquez Losada
- Department of Dermatology, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain; (C.G.O.); (B.G.-V.); (J.A.P.); (B.V.L.); (C.G.d.C.); (S.R.L.); (Á.d.D.V.); (L.P.G.); (S.G.D.); (F.V.L.)
| | - Celia Gómez de Castro
- Department of Dermatology, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain; (C.G.O.); (B.G.-V.); (J.A.P.); (B.V.L.); (C.G.d.C.); (S.R.L.); (Á.d.D.V.); (L.P.G.); (S.G.D.); (F.V.L.)
| | - Sheila Requena López
- Department of Dermatology, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain; (C.G.O.); (B.G.-V.); (J.A.P.); (B.V.L.); (C.G.d.C.); (S.R.L.); (Á.d.D.V.); (L.P.G.); (S.G.D.); (F.V.L.)
| | - Álvaro de Dios Velázquez
- Department of Dermatology, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain; (C.G.O.); (B.G.-V.); (J.A.P.); (B.V.L.); (C.G.d.C.); (S.R.L.); (Á.d.D.V.); (L.P.G.); (S.G.D.); (F.V.L.)
| | - Laura Palacios García
- Department of Dermatology, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain; (C.G.O.); (B.G.-V.); (J.A.P.); (B.V.L.); (C.G.d.C.); (S.R.L.); (Á.d.D.V.); (L.P.G.); (S.G.D.); (F.V.L.)
| | - Lucía Ordoñez Fernández
- Clinical Management Unit, UGC Farmacia, Hospital Universitario Central de Asturias, 33011 Oviedo, Asturias, Spain;
| | - Santiago Gómez Diez
- Department of Dermatology, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain; (C.G.O.); (B.G.-V.); (J.A.P.); (B.V.L.); (C.G.d.C.); (S.R.L.); (Á.d.D.V.); (L.P.G.); (S.G.D.); (F.V.L.)
| | - Francisco Vázquez López
- Department of Dermatology, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain; (C.G.O.); (B.G.-V.); (J.A.P.); (B.V.L.); (C.G.d.C.); (S.R.L.); (Á.d.D.V.); (L.P.G.); (S.G.D.); (F.V.L.)
- Area of Dermatology, Department of Medicine, University of Oviedo, 33011 Oviedo, Asturias, Spain
| | - Jorge Santos-Juanes
- Department of Dermatology, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain; (C.G.O.); (B.G.-V.); (J.A.P.); (B.V.L.); (C.G.d.C.); (S.R.L.); (Á.d.D.V.); (L.P.G.); (S.G.D.); (F.V.L.)
- Area of Dermatology, Department of Medicine, University of Oviedo, 33011 Oviedo, Asturias, Spain
- Instittudo de Investigadión Sanitaria del Principado de Asturia (ISPA), Instituto Universitario Oncológico del Principado de Asturias (IUOPA), 33011 Oviedo, Asturias, Spain
- Correspondence:
| |
Collapse
|
4
|
Chopra A, Mitra D, Agarwal R, Saraswat N, Chemburkar P, Sharma L. Real-life Efficacy and Safety of Biosimilar Adalimumab (ZRC-3197) in Patients with Plaque Psoriasis: A Tertiary Care Center Experience. Indian Dermatol Online J 2020; 11:182-186. [PMID: 32477976 PMCID: PMC7247647 DOI: 10.4103/idoj.idoj_120_19] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
Background Adalimumab is proven to be safe and effective in treating plaque psoriasis. A biosimilar adalimumab (ZRC-3197; Exemptia™) - approved by Indian Regulators in 2014 - is a 'fingerprint match' of the reference adalimumab in terms of purity, potency, safety, and clinical efficacy. While reference adalimumab remains unavailable, this biosimilar adalimumab (bADA) serves as an accessible, cost-effective option for Indian patients. This is a first-hand, prospective, real-life data on the clinical use of bADA in Indian patients with plaque psoriasis. Materials and Methods Patients with moderate-to-severe plaque psoriasis were prospectively treated with bADA therapy for 16 weeks-80 mg subcutaneously initially, followed by 40 mg every other week from week 1 in real-life setting. Psoriasis Area and Severity Index (PASI) responses, Dermatology Life Quality Index (DLQI) outcomes, and Physician's Global Assessment (PGA) for psoriasis were analyzed. Safety and tolerability evaluations included reported adverse events. Results A total of 29 patients (15 males) with median age of 38 (25-56) years were included. After 16 weeks of bADA treatment, 93% patients achieved ≥75% reduction in their baseline PASI scores including PASI75, PASI90, and PASI100 responses in 24%, 14%, and 55% patients, respectively. About 52% patients had a DLQI score of 0/1 and 93% patients had a PGA score of 'clear or minimal' at 16 weeks. Treatment was well tolerated with no severe or serious adverse reactions requiring therapy discontinuation. Conclusions This report serves as a real-life evidence for the efficacy and tolerability of biosimilar adalimumab administered for 16 weeks in patients with plaque psoriasis.
Collapse
Affiliation(s)
- Ajay Chopra
- Department of Dermatology, Base Hospital Delhi Cantt, New Delhi, India
| | - Debdeep Mitra
- Department of Dermatology, Base Hospital Delhi Cantt, New Delhi, India
| | - Reetu Agarwal
- Department of Dermatology, Base Hospital Delhi Cantt, New Delhi, India
| | - Neerja Saraswat
- Department of Dermatology, Base Hospital Delhi Cantt, New Delhi, India
| | - Pooja Chemburkar
- Department of Dermatology, Base Hospital Delhi Cantt, New Delhi, India
| | - Loknandini Sharma
- Department of Dermatology, Base Hospital Delhi Cantt, New Delhi, India
| |
Collapse
|
5
|
Seneschal J, Lacour JP, Bewley A, Faurby M, Paul C, Pellacani G, De Simone C, Horne L, Sohrt A, Augustin M, Hammond E, Reich K. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL). J Eur Acad Dermatol Venereol 2020; 34:2566-2573. [PMID: 32364296 PMCID: PMC7818467 DOI: 10.1111/jdv.16568] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2019] [Accepted: 03/27/2020] [Indexed: 12/16/2022]
Abstract
Background Anti‐tumour necrosis factor (TNF) and anti‐interleukin (IL)‐12/23 biologics revolutionized plaque psoriasis treatment by enabling ≥75% improvement in the Psoriasis Area and Severity Index (PASI 75) in clinical trials. Modern biologics are now reported to achieve PASI 100 (complete skin clearance) in clinical trials. However, real‐world evidence of skin clearance rates with biologics is limited. PSO‐BIO‐REAL was conducted to understand the real‐world burden of plaque psoriasis. Objective The primary objective of this observational study was to estimate the proportion of patients who achieved complete skin clearance at 6 months. Secondary objectives included maintenance of response and evaluation of complete skin clearance at 12 months. Methods PSO‐BIO‐REAL was a multinational, prospective, real‐world, non‐interventional study of skin clearance and patient‐reported outcomes (PROs) with biologics. A total of 846 patients from the United States (32%), France (28%), Italy (22%), the United Kingdom (11%) and Germany (8%) were enrolled and followed for one year. Eligible patients were aged ≥18 years with moderate‐to‐severe plaque psoriasis who had initiated a biologic for plaque psoriasis. Patients could be biologic‐naïve or switching biologics (biologic‐experienced). Assessments were made at baseline and at months 6 and 12. Results At 6 and 12 months, 23% and 26% of patients achieved complete skin clearance, respectively. Prior to study entry, 60% were biologic‐naïve. The proportion of patients achieving complete skin clearance was lower among biologic‐experienced patients (20% at both months 6 and 12) compared with biologic‐naïve patients (25% at month 6, 30% at month 12). The rate of complete skin clearance decreased as the number of prior biologics and baseline comorbidities increased. Conclusion Only one in four patients achieved complete skin clearance after 6 months of treatment with biologics. The study indicates there still is an unmet need for more efficacious biologics for patients with psoriasis.
Collapse
Affiliation(s)
- J Seneschal
- Department of Dermatology and Paediatric Dermatology, National Reference Centre for Rare Skin Diseases, Saint-André Hospital, University of Bordeaux, Bordeaux, France
| | - J-P Lacour
- Department of Dermatology, Archet 2 Hospital, University Hospital of Nice, Nice, France
| | - A Bewley
- Department of Dermatology, Barts Health NHS Trust London, London, UK
| | - M Faurby
- LEO Pharma A/S, Ballerup, Denmark
| | - C Paul
- Toulouse University and Larrey Hospital, Toulouse, France
| | - G Pellacani
- Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy
| | - C De Simone
- Department of Dermatology, Catholic University of the Sacred Heart, Fondazione Policlinico Universitario "A. Gemelli", IRCCS, Rome, Italy
| | - L Horne
- AstraZeneca, Gaithersburg, MD, USA
| | - A Sohrt
- LEO Pharma A/S, Ballerup, Denmark
| | - M Augustin
- Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Centre Hamburg-Eppendorf (UKE), Hamburg, Germany
| | | | - K Reich
- Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, and Skinflammation® Center, Hamburg, Germany
| |
Collapse
|
6
|
Leman J, Walton S, Layton AM, Ward KA, McBride S, Cliff S, Downs A, Landeira M, Bewley A. The real world impact of adalimumab on quality of life and the physical and psychological effects of moderate-to-severe psoriasis: a UK prospective, multicenter, observational study. J DERMATOL TREAT 2019; 31:213-221. [PMID: 30897016 DOI: 10.1080/09546634.2019.1592096] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Psoriasis can adversely affect quality of life (QoL) and emotional well-being. In this UK prospective observational study we evaluated the 'real-world' impact of adalimumab on QoL and the physical/psychological effects of moderate-to-severe psoriasis. Hundred and forty-three biologic-naïve patients with moderate-to-severe psoriasis, receiving adalimumab in clinical practice, were included. Patients completed a series of questionnaires at baseline (adalimumab initiation), 4 and 16-weeks and 6-months post-adalimumab initiation during routine visits. The main outcome measure was the proportion of Dermatology Life Quality Index (DLQI) 'responders' at 16 weeks, defined as ≥5 point reduction from baseline or DLQI = 0.90% (95% CI = 80.8%-94.6%) of evaluable patients were DLQI responders at 16-weeks. There were significant improvements at 16 weeks in patient-reported measures of QoL, mental and physical well-being, cutaneous body image, anxiety, depression and psoriasis severity, which were maintained at 6-months. Adalimumab treatment was associated with improvements in patients' QoL and psychological functioning, which occurred contemporaneously with improvements in cutaneous disease.
Collapse
Affiliation(s)
- Joyce Leman
- Department of Dermatology, Western Infirmary, Glasgow, United Kingdom
| | - Shernaz Walton
- Department of Dermatology, Castle Hill Hospital, East Yorkshire, United Kingdom
| | - Alison M Layton
- Department of Dermatology, Harrogate and District NHS Foundation Trust, Harrogate, United Kingdom
| | - Kathleen A Ward
- Department of Dermatology, Cannock Chase Hospital, Cannock, United Kingdom
| | - Sandy McBride
- Department of Dermatology, The Royal Free Hospital, London, United Kingdom
| | - Sandeep Cliff
- Department of Dermatology, East Surrey Hospital, Redhill, United Kingdom
| | - Anthony Downs
- Department of Dermatology, Royal Devon & Exeter Hospital, Exeter, United Kingdom
| | | | - Anthony Bewley
- Department of Dermatology, Barts Health NHS Trust (Whipps Cross and Royal London Hospitals), London, United Kingdom
| |
Collapse
|
7
|
Talamonti M, Galluzzo M, Bernardini N, Caldarola G, Persechino S, Cantoresi F, Egan C, Potenza C, Peris K, Bianchi L. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. J Eur Acad Dermatol Venereol 2018; 32:1737-1744. [DOI: 10.1111/jdv.15077] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2018] [Accepted: 05/04/2018] [Indexed: 01/13/2023]
Affiliation(s)
- M. Talamonti
- Department of Dermatology; University of Rome ‘Tor Vergata’; Rome Italy
| | - M. Galluzzo
- Department of Dermatology; University of Rome ‘Tor Vergata’; Rome Italy
| | - N. Bernardini
- Department of Medical and Surgical Sciences and Biotechnologies; Division of Dermatology ‘Daniele Innocenzi’; University of Rome ‘La Sapienza’; Polo Pontino Italy
| | - G. Caldarola
- Institute of Dermatology; Catholic University of the Sacred Heart; Rome Italy
| | - S. Persechino
- Department of Dermatology; NESMOS Unit; Sant'Andrea Hospital; Sapienza University of Rome; Rome Italy
| | - F. Cantoresi
- Department of Dermatology; Policlinico Umberto I; ‘Sapienza’ University of Rome; Rome Italy
| | | | - C. Potenza
- Department of Medical and Surgical Sciences and Biotechnologies; Division of Dermatology ‘Daniele Innocenzi’; University of Rome ‘La Sapienza’; Polo Pontino Italy
| | - K. Peris
- Institute of Dermatology; Catholic University of the Sacred Heart; Rome Italy
| | - L. Bianchi
- Department of Dermatology; University of Rome ‘Tor Vergata’; Rome Italy
| |
Collapse
|
8
|
Adenubiova E, Arenberger P, Gkalpakioti P, Arenbergerova M, Jircikova J, Dolezal T, Gkalpakiotis S. Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech Republic. J DERMATOL TREAT 2018; 29:579-582. [PMID: 29307245 DOI: 10.1080/09546634.2018.1425358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
BACKGROUND Adalimumab therapy has an established record of high efficacy in psoriasis treatment. However, only a limited number of studies have investigated long-term results in clinical practice. OBJECTIVES To evaluate the effectiveness and safety of adalimumab in a center for biological therapy in the Czech Republic. METHODS Retrospectively, we analyzed 90 patients with moderate to severe psoriasis who were treated with adalimumab between 2008 and 2016. The proportion of patients achieving PASI75, 90, and 100 after 3, 6, 12, 18, 24, 30, and 36 months was determined. RESULTS The mean period of treatment was 4.4 years (maximum duration reached was 8.6 years). PASI75 was observed in 85.6% of patients after 3 months, PASI90 in 50%, and PASI100 in 23.3%. Throughout the 3-year analysis, PASI90 was persistent in 91.4% and PASI100 in 51.7%. The majority of patients who reached PASI100 showed a trend to maintain the response in the long-term follow-up. No safety issues were identified. CONCLUSIONS Adalimumab is effective and safe in the long-term treatment of psoriatic patients in daily clinical practice. Once patients achieved PASI100, they tended to remain stable in treatment.
Collapse
Affiliation(s)
- Elizabeth Adenubiova
- a Department of Dermatovenereology, Third Faculty of Medicine , Charles University and Faculty Hospital of Kralovske Vinohrady , Prague , Czech Republic
| | - Petr Arenberger
- a Department of Dermatovenereology, Third Faculty of Medicine , Charles University and Faculty Hospital of Kralovske Vinohrady , Prague , Czech Republic
| | - Petra Gkalpakioti
- a Department of Dermatovenereology, Third Faculty of Medicine , Charles University and Faculty Hospital of Kralovske Vinohrady , Prague , Czech Republic
| | - Monika Arenbergerova
- a Department of Dermatovenereology, Third Faculty of Medicine , Charles University and Faculty Hospital of Kralovske Vinohrady , Prague , Czech Republic
| | | | | | - Spyridon Gkalpakiotis
- a Department of Dermatovenereology, Third Faculty of Medicine , Charles University and Faculty Hospital of Kralovske Vinohrady , Prague , Czech Republic
| |
Collapse
|
9
|
Potenza MC, Peris K, Berardesca E, Bianchi L, Richetta A, Bernardini N, De Simone C, Teoli M, Zangrilli A, D'epiro S, Orsini D, Narcisi A, Chimenti S, Costanzo A. Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey. Dermatol Ther 2017; 31. [DOI: 10.1111/dth.12565] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2017] [Revised: 05/31/2017] [Accepted: 09/26/2017] [Indexed: 11/27/2022]
Affiliation(s)
- Maria C. Potenza
- UOC di Dermatologia “Daniele Innocenzi”, Università degli Studi “Sapienza” Roma I facoltà di Medicina e Chirurgia, Polo Pontino; Terracina LT Italy
| | - Ketty Peris
- Istituto di Dermatologia Policlinico Gemelli; Rome Italy
| | | | - Luca Bianchi
- Clinica Dermatologica, Dipartimento di Medicina dei Sistemi, Universita Tor Vergata; Rome Italy
| | - Antonio Richetta
- Clinica Dermatologica, Dipartimento di Medicina dei Sistemi, Universita Tor Vergata; Rome Italy
- Centro psoriasi, Dipartimento di Medicina Interna e Specialità Mediche, Università “La Sapienza” Policlinico Umberto I; Rome Italy
| | - Nicoletta Bernardini
- UOC di Dermatologia “Daniele Innocenzi”, Università degli Studi “Sapienza” Roma I facoltà di Medicina e Chirurgia, Polo Pontino; Terracina LT Italy
| | | | - Miriam Teoli
- Clinica Dermatologica, Dipartimento di Medicina dei Sistemi, Universita Tor Vergata; Rome Italy
| | - Arianna Zangrilli
- Clinica Dermatologica, Dipartimento di Medicina dei Sistemi, Universita Tor Vergata; Rome Italy
| | - Sara D'epiro
- Centro psoriasi, Dipartimento di Medicina Interna e Specialità Mediche, Università “La Sapienza” Policlinico Umberto I; Rome Italy
| | - Diego Orsini
- Clinica Dermatologica, Dipartimento di Neuroscienze Salute Mentale e Organi di Senso (NESMOS); Università Sapienza- Azienda Ospedaliera Sant'Andrea; Rome Italy
| | - Alessandra Narcisi
- Clinica Dermatologica, Dipartimento di Neuroscienze Salute Mentale e Organi di Senso (NESMOS); Università Sapienza- Azienda Ospedaliera Sant'Andrea; Rome Italy
- Humanitas Clinical and Research Center; Skin Pathology Lab; Rozzano-Milan Italy
| | - Sergio Chimenti
- Clinica Dermatologica, Dipartimento di Medicina dei Sistemi, Universita Tor Vergata; Rome Italy
| | - Antonio Costanzo
- Humanitas Clinical and Research Center; Skin Pathology Lab; Rozzano-Milan Italy
- Dermatology Unit, Department of Biomedical Sciences; Humanitas University; Rozzano-Milan Italy
| |
Collapse
|
10
|
Carretero G, Puig L, Carrascosa JM, Ferrándiz L, Ruiz-Villaverde R, de la Cueva P, Belinchon I, Vilarrasa E, Del Rio R, Sánchez-Carazo JL, López-Ferrer A, Peral F, Armesto S, Eiris N, Mitxelena J, Vilar-Alejo J, A Martin M, Soria C. Redefining the therapeutic objective in psoriatic patients candidates for biological therapy. J DERMATOL TREAT 2017; 29:334-346. [PMID: 29099667 DOI: 10.1080/09546634.2017.1395794] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
The advances in psoriasis management currently allow achieving a good control of the disease. In particular, with the latest developed molecules, available evidence suggests that it is possible to pose an ambitious therapeutic goal, such as a Dermatology Life Quality Index 0/1, a Physician Global Assessment 0/1, or a Psoriasis Area and Severity Index 90/100 response. However, patients often fail to achieve the complete clearance of their cutaneous lesions or the improvement of disease factors that impair their quality of life. To optimize the treatment of psoriasis, it is not enough to define precisely the therapeutic objective, but also to adapt the therapeutic strategy to make the necessary modifications in case of not achieving it at the time point (at the end of the induction phase, or every 3-6 months) to be agreed with the patient (the so-called treat-to-target approach). In the present report, based on the Delphi methodology, 11 dermatologists from the Spanish Psoriasis Group addressed key issues that could be involved in the achievement and maintenance of the therapeutic goals of patients with moderate to severe psoriasis. The document provides 27 consensus statements intended to support clinical decision-making by healthcare professionals for patients who might be candidates to receive biologic therapy.
Collapse
Affiliation(s)
- G Carretero
- a Hospital Universitario de Gran Canaria Doctor Negrín , Las Palmas de Gran Canaria , Spain
| | - L Puig
- b Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona , Barcelona , Spain
| | - J M Carrascosa
- c Hospital Universitari Germans Trias I Pujol, Universitat Autònoma de Barcelona , Badalona , Spain
| | - L Ferrándiz
- d Hospital Universitario Virgen Macarena , Sevilla , Spain
| | | | - P de la Cueva
- f Hospital Universitario Infanta Leonor , Madrid , Spain
| | - I Belinchon
- g Hospital General Universitario de Alicante-ISABIAL , Alicante , Spain
| | - E Vilarrasa
- b Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona , Barcelona , Spain
| | - R Del Rio
- h Fundació Hospital L'Esperit Sant , Santa Coloma de Gramenet , Spain
| | | | - A López-Ferrer
- b Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona , Barcelona , Spain
| | - F Peral
- j Hospital Universitario Infanta Cristina de Badajoz , Badajoz , Spain
| | - S Armesto
- k Hospital Universitario Marqués de Valdecilla , Santander , Spain
| | - N Eiris
- l Complejo Asistencial Universitario de León , Spain
| | | | - J Vilar-Alejo
- a Hospital Universitario de Gran Canaria Doctor Negrín , Las Palmas de Gran Canaria , Spain
| | - M A Martin
- n Hospital Clínico Universitario Lozano Blesa , Zaragoza , Spain
| | - C Soria
- o Hospital General Universitario Reina Sofia , Murcia , Spain
| | | |
Collapse
|
11
|
Carrera CG, Dapavo P, Malagoli P, Naldi L, Arancio L, Gaiani F, Egan CG, Di Mercurio M, Cattaneo A. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis. J DERMATOL TREAT 2017; 29:481-486. [DOI: 10.1080/09546634.2017.1395805] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Carlo Giovanni Carrera
- U.O. Dermatologia, Fondazione IRCCS Cà Granda – Ospedale Maggiore Policlinico, Milan, Italy
| | - Paolo Dapavo
- Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy
| | | | - Luigi Naldi
- U.O.C. Dermatologia, Ospedale San Bortolo – Azienda ULSS8, Berica (VI), Italy
| | - Luisa Arancio
- U.O. Dermatologia, Fondazione IRCCS Cà Granda – Ospedale Maggiore Policlinico, Milan, Italy
| | - Francesca Gaiani
- Dermatology Unit, Azienda Ospedaliera San Donato Milanese, Milan, Italy
| | | | | | - Angelo Cattaneo
- U.O. Dermatologia, Fondazione IRCCS Cà Granda – Ospedale Maggiore Policlinico, Milan, Italy
| |
Collapse
|
12
|
Havmose M, Thomsen SF. Development of paradoxical inflammatory disorders during treatment of psoriasis with TNF inhibitors: a review of published cases. Int J Dermatol 2017; 56:1087-1102. [DOI: 10.1111/ijd.13691] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/10/2016] [Revised: 03/18/2017] [Accepted: 05/22/2017] [Indexed: 12/29/2022]
Affiliation(s)
- Martin Havmose
- Department of Dermatology; Bispebjerg Hospital; Copenhagen Denmark
| | - Simon Francis Thomsen
- Department of Dermatology; Bispebjerg Hospital; Copenhagen Denmark
- Department of Biomedical Sciences; University of Copenhagen; Copenhagen Denmark
| |
Collapse
|
13
|
Chiricozzi A, Zangrilli A, Bavetta M, Bianchi L, Chimenti S, Saraceno R. Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study. J Eur Acad Dermatol Venereol 2016; 31:304-311. [DOI: 10.1111/jdv.13771] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2015] [Accepted: 04/19/2016] [Indexed: 12/24/2022]
Affiliation(s)
- A. Chiricozzi
- Dermatology Department; University of Pisa; Pisa Italy
| | - A. Zangrilli
- Department of Dermatology; University of Rome Tor Vergata; Rome Italy
| | - M. Bavetta
- Department of Dermatology; University of Rome Tor Vergata; Rome Italy
| | - L. Bianchi
- Department of Dermatology; University of Rome Tor Vergata; Rome Italy
| | - S. Chimenti
- Department of Dermatology; University of Rome Tor Vergata; Rome Italy
| | - R. Saraceno
- Department of Dermatology; University of Rome Tor Vergata; Rome Italy
| |
Collapse
|